Anti-invasive and anti-metastasis strategies: New roads, new tools and new hopes

Current Cancer Drug Targets

Volumn 6, Issue 8, 2006, Pages 729-751

  Dollé, Laurent ^a   Depypere, Herman T ^a   Bracke, Marc E ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Cancer; Cytoskeleton; Invasion; Metastasis; Metastasis related genes; Microecosystem; Microenvironment; Migration

Indexed keywords

1 (5 CHLORO 1 NAPHTHALENESULFONYL)HEXAHYDRO 1H 1,4 DIAZEPINE; 2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; 4 [6 METHOXY 7 [3 (1 PIPERIDINYL)PROPOXY] 4 QUINAZOLINYL] 1 PIPERAZINECARBOXYLIC ACID (4 ISOPROPOXYPHENYL)AMIDE; ALPHA INTERFERON; APLYRONINE A; BEVACIZUMAB; CANERTINIB; CEP 701; CETUXIMAB; CYTOCHALASIN B; DEMECOLCINE; ERLOTINIB; EVEROLIMUS; GEFITINIB; IMATINIB; KT 5926; L 778123; LAPATINIB; LAULIMALIDE; MARIMASTAT; MIDOSTAURIN; OCTREOTIDE; PACLITAXEL; SEMAXANIB; TEMSIROLIMUS; TOPOTECAN; TRASTUZUMAB; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE;

ANOIKIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER INHIBITION; CANCER INVASION; CANCER RESEARCH; CANCER THERAPY; CARCINOGENESIS; CELL ACTIVITY; CELL GROWTH; CLINICAL TRIAL; CYTOSKELETON; DRUG MECHANISM; DRUG TARGETING; GENE REPRESSION; HUMAN; METASTASIS; METASTASIS INHIBITION; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; ANOIKIS; ANTINEOPLASTIC AGENTS; CYTOSKELETON; GENES, TUMOR SUPPRESSOR; GUANOSINE TRIPHOSPHATE; HUMANS; MICROTUBULES; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; POLYSACCHARIDES; SIGNAL TRANSDUCTION;

EID: 33845347806     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/156800906779010263     Document Type: Review

References (120)

1. Hanahan, D.; Weinberg R. A. The hallmarks of cancer. Cell 2000, 100, 57-70.
2. Awada, A.; Mano, M.; Hendlisz, A.; Piccart, M. New anticancer agents and therapeutic strategies in development for solid cancers: a clinical perspective. Exp. Rev. Anticancer Ther. 2004, 4, 53-60.
3. Guillemard, V.; Saragovi, H. U. Novel approaches for targeted cancer therapy. Curr. Cancer Drug Targets 2004, 4, 313-324.
4. Joyce, J. A. Therapeutic targeting of the tumor microenvironment. Cancer Cell, 2005, 7, 513-520.
5. Liotta, L. A.; Kohn, E. The microenvironment of the tumor-host interface. Nature 2001, 430, 973-974.
6. De Wever, O.; Mareel, M. Role of myofibroblasts at the invasion front. Biol. Chem. 2002, 383, 55-67.
7. De Wever, O.; Mareel, M. Role of tissue stroma in cancer cell invasion. J. Pathol. 2003, 200, 429-447.
8. Bhowmick, N. A.; Neilson, E. G.; Moses, H. L. Stromal fibroblasts in cancer initiation and progression. Nature 2004, 432, 332-337.
9. Desmoulière, A.; Guyot, C.; Gabbiani, G. The stroma reaction myofibroblast: a key player in the control of tumor cell behaviour. Int. J. Dev. Biol. 2004, 48, 509-517.
10. Bange, J.; Zwick, E.; Ullrich, A. Molecular targets for breast cancer therapy and prevention. Nat. Med. 2001, 7, 548-552.
11. Colomer, R.; Shamon, L. A.; Tsai, M. S.; Lupu, R. Herceptin: from the bench to the clinic. Cancer Invest. 2001, 19, 49-56.
12. Dollé, L.; Adriaenssens, E.; El Yazidi-Belkoura, I.; Le Bourhis, X.; Nurcombe, V.; Hondermarck, H. Nerve growth factor receptors and signaling in breast cancer. Curr. Cancer Drug Targets 2004, 4, 463-470.
13. Dredge, K.; Dalgleish, A. G.; Mariott, J. B. Angiogenesis inhibitors in cancer therapy. Curr. Opin. Investig. Drugs 2003, 4, 667-674.
14. Ziche, M.; Donnini, S.; Morbidelli, L. Development of new drugs in angiogenesis. Curr. Drug Targets 2004, 5, 389-406.
15. Egeblad, M.; Werb, Z. New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. Cancer 2002, 2, 161-174.
16. Yana, I.; Seiki, M. MT-MMPs play pivotal roles in cancer dissemination. Clin. Exp. Metastasis 2002, 19, 209-215.
17. Guo, W.; Giancotti, F. G. Integrin signaling during tumor progression. Nat. Rev. Mol. Cell Biol. 2004, 5, 816-826.
18. Xiao, T.; Takagi, J.; Coller, B. S.; Wang, J. H.; Springer, T. A. Structural basis for allostery in integrins and binding to fibrinogen-mimetic therapeutics. Nature 2004, 432, 59-67.
19. Kinzler, K. W.; Vogelstein, B. Gatekeepers and caretakers. Nature 1997, 386, 761-763.
20. Kinzler, K. W; Volgestein, B. Landscaping the cancer terain. Science 1998, 280, 1036-1037.
21. Bissel, M. J.; Radisky, D. Putting tumors in context. Nat. Rev. Cancer 2001, 1, 46-54.
22. Eisenberg, D.; Marcotte, E. M.; Xenarios, I.; Yeates, T. O. Protein function in the post-genomic era. Nature 2000, 405, 823-826.
23. Hondermarck, H. Eds. Proteomics: Biomedical and Pharmaceutical Applications; Kluwer Academic Publishers: Netherlands, 2004.
24. Alessandro, R.; Fontana, S.; Khon, E.; De Leo, G. Proteomic strategies and their application in cancer research. Tumori 2005, 91, 447-455.
25. Petricoin, E. F.; Zoon, K. C.; Kohn, E. C.; Barett, J. C.; Liotta, L. A. Clinical proteomics: translating benchside promise into bedside reality. Nat. Rev. Drug Discov. 2004, 1, 683-695.
26. Sawyers, C. Targeted cancer therapy. Nature 2004, 432, 294-297.
27. Descamps, S.; Lebourhis, X.; Delehedde, M.; Boilly, B.; Hondermarck, H. Nerve Growth Factor is mitogenic for cancerous but not normal human breast epithelial cells. J. Biol. Chem. 1998, 273, 16659-16662.
28. Descamps, S.; Toillon, R. A.; Adriaenssens, E.; Pawlowski, V.; Cool, S. M.; Nurcombe, V.; Lebourhis, X.; Boilly, B.; Peyrat, J. P.; Hondermarck, H. Nerve Growth Factor stimulates proliferation and survival off human breast cancer cells trough two distinct signaling pathways. J. Biol. Chem. 2001, 276, 17864-17870.
29. Dollé, L.; El Yazidi-Belkoura, I.; Adriaenssens, E.; Nurcombe, V.; Hondermarck, H. Nerve growth factor overexpression and autocrine loop in breast cancer cells. Oncogene 2003, 22, 5592-5601.
30. Dollé, L.; Oliveira, M. J.; Bruyneel, E.; Hondermarck, H.; Bracke, M. E. Nerve Growth Factor mediates its pro-invasive effect in parallel with the release of a soluble E-cadherin fragment from breast cancer MCF-7/AZ cells. J. Dairy Res. 2005, 72, 20-26.
31. Saragovi, H. U.; Gehring, K. Development of pharmacological agents for targeting neurotrophins and their receptors. Trends Pharmacol. Sci. 2000, 21, 93-98.
32. Zhu, Z.; Bohlen, P.; White, L. Clinical development of angiogenesis inhibitors to Vascular Endothelial Growth Factor and its receptors as cancer therapeutics. Curr. Cancer Drug Targets 2002, 3, 338-344.
33. Wylie, S.; MacDonald, I. C.; Varghese, H. J.; Schmidt, E. E.; Morris, V. L.; Groom, A. C.; Chambers, A. F. The matrix metalloproteinases inhibitor batimastat inhibits angiogenesis in liver metastases of B16F1 melanoma cells. Clin. Exp. Metastasis 1999, 17, 111-117.
34. Paget, S. The distribution of secondary growths in cancer of the breast. Lancet 1889, 1, 571-573.
35. Matrisian, L. M.; Cunha, G. R.; Mohla, S. Epithelial-stromal interactions and tumor progression: meeting summary and future directions. Cancer Res. 2001, 61, 3844-3846.
36. Fidler, I. J. The organ microenvironment and cancer metastasis. Differentiation 2002, 70, 498-505.
37. De Wever, O.; Nguyen, Q. D.; Van Hoorde, L.; Bracke, M. E.; Bruyneel, E.; Gespach, C.; Mareel, M. Tenascin-C and SF-HGF produced by myofibroblasts in vitro provide convergent proinvasive signals to human colon cancer cells through RhoA and Rac. FASEB J. 2004, 18, 1016-1018.
38. Engers, R.; Gabbert, H. E. Mechanisms of tumor metastasis: cell biological aspects and clinical implications. J. Cancer Res. Clin. Oncol. 2000, 126, 682-692.
39. Mareel, M.; Leroy, A. Clinical, cellular, and molecular aspects of cancer invasion. Physiol. Rev. 2003, 83, 337-376.
40. Wyckoff, J. B.; Jones, J. G.; Condeelis, J. S.; Segall, J. E. A critical step in metastasis: in vivo analysis of intravasation at the primary tumor. Cancer Res. 2000, 60, 2504-2511.
41. Chambers, A. F.; Groom, A. C.; MacDonald, I. C. Dissemination and growth of cancer cells in metastatic sites. Nat. Rev. Cancer. 2002, 2, 563-572.
42. Liotta L. A.; Kohn E. Anoikis: cancer and the homeless cell. Nature 2004, 430, 973-974.
43. Cavallaro, U.; Christofori, G. Cell adhesion in tumor invasion and metastasis: loss of the glue is not enough. Br. J. Cancer 2001, 1552, 39-45.
44. Bryant, D. M.; Stow, J. L. The ins and outs of E-cadherin trafficking. TRENDS Cell Biol. 2004, 14, 427-434.
45. Miranda, K. C.; Khromykh, T.; Christy, P.; Le, T. L.; Gottardi, C. J.; Yap, A. S.; Stow, J. L.; Teasdale, R. D. A dileucine motif targets E-cadherin to the basolateral cell surface in Madine-Darby canine kidney and LLC-PK1 epithelial cells. J. Biol. Chem. 2001, 276, 22565-22572.
46. Blobel, C. P. Remarkable roles of proteolysis on and beyond the cell surface. Curr. Opini. Cell Biol. 2000, 12, 606-612.
47. Marambaud, P.; Shioi, J.; Serban, G.; Georgekopoulos, A.; Sarner, S.; Nagy, V.; Baki, L.; Wen, P.; Efthimiopoulos, S.; Shao, Z.; Wisniewski, T.; Robakis, N. K. A presenilin-1/gamma-secretase cleavage releases the E-cadherin intracellular domain and regulates disassembly of adherens junctions. EMBO J. 2002, 21, 1948-1956.
48. Vleminckx, K. L.; Deman, J. J.; Bruyneel, E.; Vandenbossche, G. M.; Keirsebilck, A. A.; Mareel, M. M.; Van Roy, F. M. Enlarged cell-associated proteoglycans abolish E-cadherin functionality in invasive tumor cells. Cancer Res. 1994, 54, 873-877.
49. Wesseling, J.; Van der Valk, S. W.; Hilkens, J. A mechanism for inhibition of E-cadherin-mediated ceel-cell adhesion by the membrane-associated mucin episialin/MUC1. Mol. Biol. Cell 1996, 7, 565-577.
50. Truant, S.; Bruyneel, E.; Gouyer, V.; De Wever, O.; Pruvot, F. R.; Mareel, M.; Huet, G. Requirement of both mucins and proteoglycans in cell-cell dissociation and invasiveness of colon carcinoma HT-29 cells. Int. J Cancer 2003, 104, 683-694.
51. Li, Y.; Bharti, A.; Chen, D.; Gong, J.; Kufe, D. Interaction of glycogen synthase kinase 3beta with the DF3/MUC1 carcinoma-associated antigen and beta-catenin. Mol. Cell Biol. 1998, 18, 7216-7224.
52. Gronborg, M.; Kristiansen, T. Z.; Iwahori, A.; Chang, R.; Reddy, R.; Sato, N.; Molina, H.; Jensen, O. N.; Hruban, R. H.; Goggins, M. G.; Maitra, A.; Pandy, A. Biomarkers discovery from pancreatic cancer secretome using a differential proteomics approach. Mol. Cell Proteomics 2006, 5, 157-171.
53. Frisch, S. M.; Screaton R.A. Anoikis mechanisms. Curr. Opini. Cell Biol. 2001, 13, 555-562.
54. Cory, S.; Adams, J. M. The Bcl2 family: regulators of the cellular life-or-death switch. Nat. Rev. Cancer 2002, 2, 647-656.
55. Matter, M. L.; Ruoslahti, E. A signaling pathway from the alpha5beta1 and alphaVbeta3 integrins that elevates bcl2 transcription. J. Biol. Chem. 2001, 276, 27757-27763.
56. Jan, Y.; Matter, M.; Pai J. T.; Chen, Y. L.; Pilch, J.; Komatsu, M.; Ong, E.; Fukuda, M.; Ruoslahti, E. A mitochondrial protein, Bit1, mediates apoptosis regulated by integrins and Groucho/TLE corepressors. Cell 2005, 116, 751-762.
57. Douma, S.; van Laar, T.; Zevenhoven, J.; Meuwissen, R.; van Garderen, E.; Peeper, D. S. Suppression of anoikis and induction of metastasis by the neurotrophic receptor TrkB. Nature 2004, 430, 1034-1039.
58. Blank, M.; Blind, M. Aptamers as tools for target validation. Curr. Opin. Chem. Biol. 2005, 9, 336-342.
59. Wymann, M. P.; Marone, R. Phosphoinositide 3-kinase in disease: timing, location, and scaffolding. Curr. Opini. Cell Biol. 2005, 17, 141-149.
60. Coussens, L. M.; Fingleton, B., Matrisian, L. M. Matrix metalloproteinase inhibitors and cancer. Science 2002, 295, 2387-2392.
61. Overall, C. M.; Lopez-Otin, C. Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat. Rev. Cancer 2002, 2, 657-672.
62. Loppez-Ottin, C.; Overall, C. M. Protease degradomics: a new challenge for proteomics. Nat. Rev. Cancer 2002, 3, 509-519.
63. Eble, J. A.; Haier, J. Integrins in cancer treatment. Curr. Cancer Drug Targets 2006, 6, 89-105.
64. Jin, H.; Varner, J. Integrins: roles in cancer development and as treatment targets. Br. J. Cancer 2004, 90, 561-565.
65. Sethi, T.; Rintoul, R. C.; Moore, S. M.; MacKinnon, A. C.; Salter, D.; Choo, C.; Chilvers, E. R.; Dransfield, I.; Donnelly, S. C.; Strieter, R.; Haslett, C. Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: a mechanism for small cell lung cancer growth and drug resistance in vivo. Nat. Med. 1999, 7, 186-191.
66. Scott, A. M.; Wiseman, G.; Welt, S.; Adjei, A.; Lee, F. T.; Hopkins, W.; Divgi, C. R.; Hanson, L. H.; Mitchell, P.; Gansen, D. N.; et al. A phase I dose-escalation study of sibrotuzubmab in patients with advanced or metastatic fibroblast activation protein-positive cancer. Clin. Cancer Res. 2003, 9, 1639-1647.
67. Steppan, C. M.; Bailey, S. T.; Bhat, S.; Brown, E. J.; Banerjee, R. R.; Wright, C. M.; Patel, H. R.; Ahima, R. S.; Lazar, M. A. The hormone resistin links obesity to diabetes. Nature 2001, 409, 292-293.
68. Iyengar, P.; Espina, V.; Williams, T. W.; Lin, Y.; Berry, D.; Jelicks, L. A.; Lee, H.; Temple, K. Graves, R.; Pollard, J.; Chopra, N.; Russell, R. G.; Sasisekharan, R.; Trock, B. J.; Lippman, M.; Calvert, V. S.; Petricoin, E. F. 3rd; Liotta, L.; Dadachova, E.; Pestell, R. G.; Lisanti, M. P.; Bonaldo, P.; Schere, P. E. Adipocyte-derived collagen VI affects early mammary tumor progression in vivo, demonstrating a critical ineraction in the tumor/stroma microenironment. J. Clin. Invest. 2005, 115, 1163-1176.
69. Carmeliet, P.; Jain, R. K. Angiogenesis in cancer and other diseases. Nature 2000, 407, 249-257.
70. Hollingsworth, M. A.; Swanson, B.J. Mucins in cancer: protection and control of the cell surface. Nat. Rev. Cancer 2004, 4, 45-60.
71. Fuster, M. M.; Esko, J. D. The sweet and sour of cancer: glycans as novel therapeutic targets. Nat. Rev. Cancer 2005, 5, 526-542.
72. Yoshimura, M.; Ihara, Y.; Matsuzawa, Y.; Tanigushi, N. Aberrant glycosylation of E-cadherin enhances cell-cell binding to suppress metastasis. J. Biol. Chem. 1996, 271, 13811-13815.
73. Guo, H. B.; Lee, I.; Kamar, M.; Akiyama, S. K.; Pierce, M. Aberrant N-glycosylation of b1 integrin causes reduced a5b1 integrin clustering and stimulated cell migration. Cancer Res. 2002, 62, 6837-6845.
74. Lin, S.; Kemmner, W.; Grigull, S.; Schlag, P. M. Cell surface α2,6 sialylation affects adhesion of breast carcinoma cells. Exp. Cell Res. 2002, 276, 101-110.
75. Julien, S.; Krzowinski-Recchi, M. A.; Harduin-Lepers, A.; Gouyer, V.; Huet, G.; Lebourhis, X.; Delannoy, P. Expression of sialyl-Tn antigen in breast cancer cells transfected with the human CMP-Neu5Ac:GalNac α2,6- sialyltransferase (S6GalNacI) cDNA. Glycoconj. J. 2001, 18, 883-893.
76. Webb, D. J.; Parsons, J. T.; Horwitz, A. F. Adhesion assembly, disassembly and turnover in migrating cells- over and over and over again. Nat. Cell Biol. 2002, 4, 97-100.
77. Ridley, A. J.; Schwartz, M. A.; Burridge, K.; Firtel, R. A.; Ginsberg, M. H.; Borisy, G.; Parsons, J. T.; Horwitz, A. R. Cell migration: integrating signals from front to back. Science 2003, 302, 1704-1709.
78. Levin, E. G. Cancer therapy through control of cell migration. Curr. Cancer Drug Targets 2005, 5, 505-518.
79. Livant, D. L. Targeting invasion induction as a therapeutic strategy for treatment of cancer. Curr. Cancer Drug Targets 2005, 5, 489-504.
80. Etienne-Manneville, S. Actin and microtubules in cell motility: which one is in control? Traffic 2004, 5, 470-477.
81. Coulombe, P. A.; Wong, P. Cytoplasmic intermediate filaments revealed as dynamic and multipurpose scaffolds. Nat. Cell Biol. 2004, 6, 699-706.
82. Fukata, M.; Nakagawa, M.; Kaibuchi, K. Roles of Rho-family GTPases in cell polarization and directional migration. Curr. Opin. Cell Biol. 2003, 15, 590-597.
83. Huttenlocher, A. Cell polarization mechanisms during directed cell migration. Nat. Cell Biol. 2005, 7, 336-337.
84. Nishiya, N.; Kiosses, W. B.; Han, J.; Ginsberg, M. H. An alpha4 integrin-paxillin-Arf-GAP complex restricts Rac activation to the leading edge of migrating cells. Nat. Cell Biol. 2005, 7, 343-352.
85. Hall, A. Rho-GTPases and the actin cytoskeleton. Science 1998, 279, 509-514.
86. Bishop, A. L.; Hall, A. Rho-GTPases and their effectors. Biochem. J. 2000, 348, 241-255.
87. Ridley, A. J. Rho GTPases and cell migration. J. Cell Sci. 2001, 114, 2713-2722.
88. Wang, W.; Goswami, S.; Sahai, E.; Wyckoff, J. B.; Segall, J. E.; Condeelis, J. S. Tumor cells caught in the act of invading: their strategy for enhanced cell motility. TRENDS in Cell Biol. 2005, 15, 138-145.
89. Fenteany, G.; Zhu, S. Small-molecule inhibitors of actin dynamics and cell motility. Curr. Topics Med. Chem. 2003, 3, 593-616.
90. Rao, J. Y.; Li, N. Microfilament actin remodelling as a target for cancer drug development. Curr. Cancer Drug Targets, 2004, 4, 345-354.
91. Sliva, D. Signaling pathways responsible for cancer cell invasion as targets for cancer therapy. Curr. Cancer Drug Targets, 2004, 4, 327-336.
92. Herrmann, C.; Wray, J.; Travers, F.; Barman, T. Effect of 2,3-butanedione monoxime on myosin and myofibrillar ATPases. An example of an uncompetitive inhibitor. Biochem. 1992, 31, 12227-12232.
93. Cheung, A.; Dantzig, J. A.; Hollingworth, S.; Baylor, S. M.; Goldman, Y. E.; Mitchison, T. J.; Straight, A. F. A small-molecule inhibitor of skeleton muscle myosin II. Nat. Cell Biol. 2002, 4, 83-88.
94. Etienne-Manneville, S.; Hall, A. Rho GTPases in cell biology. Nature 2002, 420, 629-635.
95. Goa, Y.; Dickerson, J. B.; Guo, F.; Zheng, J.; Zheng, Y. Rational design and characterization of a Rac GTPase-specific small molecule inhibitor. Proc. Natl. Acad. Sci. USA 2004, 101, 7618-7623.
96. Steeg, P. S. Metastasis suppressors pathways-an evolving paradigm. Nat. Rev. Cancer 2003, 3, 55-63.
97. Yoshida, B. A.; Sokoloff, M. M.; Welch, D. R.; Rinker-Schaeffer, C. W. Metastasis-suppressor genes: a review and perspective on an emerging field. J. Nat. Cancer Inst. 2000, 92, 1717-1730.
98. Shevde, L. A.; Welch, D. R. Metastasis suppressor pathways- an evolving paradigm. Cancer Lett. 2003, 198, 1-20.
99. Steeg, P. S.; Ouatas, T.; Halverson, D.; Palmieri, D.; Salerno, M. Metastasis suppressor genes: basic biology and potential clinical use. Clin. Breast Cancer 2003, 4, 1-12.
100. Kauffman, E. C.; Robinson, V. L.; Stadler, W. M.; Sokoloff, M. H.; Rinker-Schaeffer, C. W. Metastasis suppression: the evolving role of metastasis suppressor genes for regulating cancer cell growth at the secondary site. J. Urol. 2003, 169, 1122-1133.
101. Stark, A. M.; Tongers, K.; Maass, N.; Mehdorn, H. M.; Held-Feindt, J. Reduced metastasis-suppressor gene mRNA-expression in breast cancer brain metastases. J. Cancer Res. Clin. Oncol. 2005, 131, 191-198.
102. Graff, J. R.; Zimmer, S. G. Translational control and metastatic progression: enhanced activity of the mRNA cap-binding protein eIF-4E selectively enhances translation of metastasis-related mRNAs. Clin. Exp. Metastsis 2003, 20, 265-273.
103. Plass, C.; Soloway, P. D. DNA methylation, imprinting and cancer. Eur. J. Hum. Genet. 2002, 10, 6-16.
104. Karpf, A. R.; Jones, D. A. Reactivating the expression of methylation silenced genes in human cancer. Oncogene 2002, 21, 5496-5503.
105. Mabjeesh, N. J.; Post, D. E.; Willard, M. T.; Kaur, B.; Van Meir, E. G.; Simons, J. W.; Zhong, H. Geldanamycin induces degradation of hypoxia-inducible factor 1alpha protein via the proteosome pathway in prostate cancer cells. Cancer Res. 2002, 62, 2478-2482.
106. Hartsough, M. T.; Morrison, D.; Salerno, M.; Palmieri, D.; Ouatas, T.; Mair, M.; Patrick, J.; Steeg, P. S. Nm23-H1 metastasis suppressor phosphorylation of kinase suppressor of ras (SKR), via a histidine protein kinase pathway. J. Biol. Chem. 2002, 277, 32389-32399.
107. Hartsough, M. T.; Clare, S. E.; Mair, M.; Elkahloun, A. G.; Sgroi, D.; Osborne, C. K .; Clark, G.; Steeg, P. S. Elevation of breast carcinoma Nm23-H1 metastasis suppressor gene expression and reduced motility by DNA methylation inhibiton. Cancer Res. 2001, 61, 2320-2327.
108. Jackson, P.; Marreiros, A.; Russell, P. J. KAI1 tetraspanin and metastasis suppressor. Int. J. Biochem. Cell Biol. 2005, 37, 530-534.
109. Odintsova, E.; Suguira, T.; Berditchevski, F. Attenuation of EGF receptor signaling by a metastasis suppressor, the tetraspanin CD82/KAI1. Curr. Biol. 2000, 10, 1009-1012.
110. Keller, E. T. Metastasis suppressor genes: a role for raf kinase inhibitor protein (RKIP). Anti-Cancer Res. 2004, 15, 663-669.
111. Mitchell, D. C.; Abdebrahim, M.; Weng, J.; Stafford, L. J.; Safe, S.; Bar-Eli, M.; Liu, M. Regulation of KISS1 metastasis suppressor gene expression in breast cancer. J. Biol. Chem. 2006, 281, 51-58.
112. Ouatas, T.; Halverson, D.; Steeg, P. S. Dexamethadone and medroxyprogesterone acetate elevate Nm23-H1 metastasis suppressor expression in metastatic human breast carcinoma cells via glucocorticoid receptor-dependent: new uses for old compounds. Clin. Cancer Res. 2003, 9, 3763-3772.
113. Palmieri, D.; Halverson, D. O.; Ouatas, T.; Horak, C. E.; Salerno, M.; Johnson, J.; Figg, W. D.; Hollingshead, M.; Hursting, S.; Berrigan, D.; Steinberg, S. M.; Merino, M. J.; Steeg, P. S. Medroxyprogesterone acetate elevation of Nm23-H1 metastasis suppressor expression in hormone receptor-negative breast cancer. J. Natl. Cancer Inst. 2005, 97, 632-642.
114. Liu, F.; Qi, H. L.; Chen, H. L. Effects of all-trans retinoc acid and epidermal growth factor on the expression of Nm23-H1 in human hepatocarcinoma cells. J. Cancer Res. Clin. Oncol. 2000, 126, 85-90.
115. Jiang, W.; Redfern, A.; Bryce, R.; et al. Peroxisome proliferator activated-receptor-g (PPARg) mediates the action of gamma linolenic acid in breast cancer cells. Prostaglandins Leukot. Essent. Fatty Acids 2000, 62, 119-127.
116. Kenny, F.; Pinder, S.; Ellis, I.O; Gee, G. M.; Nicholson, R. I.; Bryce, R. P.; Robertson, J. F. Gamma linolenic acid with tamoxifen as primary therapy in breast cancer. Int. J. Cancer 2000, 85, 643-648.
117. Menendez, J.; Barbacid, M.; Montero S.; Sevilla E.; Escrich E.; Solanas M.; Cortes-Funes H.; Colomer R. Effects of gamma-linolenic acid and oleic acid on paclitaxel cytotoxicity in human breast cancer cells. Eur. J. Cancer 2001, 37, 402-413.
118. Morin, P. J. Drug resistance and the microenvironment: nature and nurture. Drug Resist. Updat. 2003, 6, 169-172.
119. Shain, K. H.; Dalton, W. S. Cell adhesion is a key determinant in de novo multidrug resistance (MDR): new targets for the prevention of acquired MDR. Mol. Cancer Ther. 2001, 1, 69-78.
120. Jain, R. K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005, 307, 58-62.